ClinicalTrials.gg
CompletedNCT04730635Updated Oct 28, 2024Results posted

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

A Phase 1 interventional study of Donepezil and Placebo in Alzheimer's Disease and Mild Cognitive Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 10 sites in 2 countries. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
37th of 58
44 · median 79
Started
2021
with 1 other
Phase 1
20 of 60
1 open now
Registered
58th of 60
by date
Lead sponsor
3 of 60
Merck Sharp & Dohme LLC

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 37th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2021, is one of 20 in phase 1, and was the 58th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among participants with mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD). The primary study hypothesis is that the average percentage of correct responses on one card learning (OCL) task will be ≥2 percentage points in participants receiving donepezil compared with participants receiving placebo.

03

Conditions studied

  • Alzheimer's Disease
  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has an (MMSE) score between 18 and 28 (inclusive) at Screening (Visit 1) and Baseline (Visit 2)
  • Has a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD)
  • Has an Modified Hachinski Ischemia Scale (MHIS) score of ≤4
  • Must have a reliable and competent study partner/informant who accompanies participant to study visits and participates in assessments
  • Be willing to provide a blood sample for Apolipoprotein E (APOE) genotyping
  • Does not have intellectual disability
  • Be able to speak, read, hear, and understand the language of the study staff and the Form (ICF)
  • Be able and willing to adhere to the study visit schedule
  • Have visual acuity, visual function, hearing, and gross and fine motor skills adequate to support study participation
  • Be capable of performing the Cogstate battery assessments, as demonstrated at the Baseline/Familiarization Visit (Visit 2)
  • A female participant is eligible to participate if she is a woman of nonchildbearing potential (WONCBP)

Exclusion criteria

Exclusion Criteria:

  • Is at imminent risk of self-harm
  • Has evidence of a neurological disorder other than AD at screening, including but not limited to: Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, dementia with Lewy bodies, other types of dementia, neurosyphilis or that led to persistent cognitive deficits, or has a history of seizures or epilepsy within the last 5 years before screening
  • Has a known history of stroke or has a diagnosis of vascular dementia
  • Has history of multiple episodes of head trauma, or head trauma resulting in protracted loss of consciousness, or serious infectious disease affecting the brain, within the prior 3-5 years
  • Has evidence of a clinically relevant or unstable psychiatric disorder, based on , 5th Edition (DSM-5), including schizophrenia or other psychotic disorder, bipolar disorder, major depression, or delirium
  • Has a recent or ongoing, uncontrolled, clinically significant medical condition within 2 months of the Screening visit
  • Has a history of cancer
  • Has a relative to donepezil including sick sinus syndrome, first, second, or third-degree heart block, bradycardia, active gastrointestinal (GI) bleeding, Zollinger-Ellison syndrome, uncontrolled peptic ulcer disease, or uncontrolled asthma
  • Has a history of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food. Exception: Participants with selected allergies may be enrolled with Sponsor's approval
  • Is positive for surface antigen (HBsAg), antibodies or (HIV) [participants with a history of chronic hepatitis C virus with a documented cure and/or a positive serologic test for HCV with a negative HCV viral load may be included]
  • Has clinically significant vitamin B12 or folate deficiency in the 6 months immediately before screening, or vitamin B12 or folate deficiency in addition to increased serum homocysteine and methylmalonic acid levels at screening
  • Has prior AD treatment
  • Has participated in another study within 4 weeks
  • Has a known history of structural changes on screening magnetic resonance imaging (MRI) scan that are clinically important, including signs indicative of vascular dementia, large infarct, lacunes in critical areas, space-occupying lesions, or extensive white matter disease
  • Is unwilling to or not eligible to undergo a MRI scan (if a prior MRI scan is not available)
  • Is pregnant, is attempting to become pregnant, or is nursing children
  • Has a history of alcoholism or drug dependency/abuse within the last 5 years prior to the Screening visit
  • Consumes greater than 3 glasses of alcoholic beverages per day
  • Consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, energy drinks, or other caffeinated beverages per day
  • Is a regular user of cannabis, any illicit drugs or has a history of drug abuse within approximately 5 years. A participant who is a recreational user of cannabis or other drugs within the past 2 years can be enrolled as long as recreational use does not meet the definition of drug abuse and participant agrees to refrain from substance use for duration of study participation
  • Participants must have a negative urine drug screen (UDS) prior to randomization
  • Had major surgery within 3 months prior to the Screening visit that would interfere in the participant's ability to fully participate in the study
  • Has undergone neuropsychological testing (including the ) or cognitive remediation in the past 4 weeks
  • Is or has an immediate family member who is investigational site or Sponsor staff directly involved with this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Donepezil

    Participants receive donepezil in doses up to 10 mg once daily (QD), orally in a scheduled titration for Days 1-56. The total treatment duration is 56 days.

    Drug: Donepezil

  • Placebo comparator
    Placebo

    Participants receive placebo QD, orally for Days 1-56. The total treatment duration is 56 Days.

    Drug: Placebo

Interventions

  • Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.

    Also known as: MK-0000, Donepezil hydrochloride, Aricept

  • DrugPlacebo

    Dose matched placebo capsule QD, orally for Days 1-56.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Averaged Correct Response Rate on the One Card Learning Task to Week 8

    One Card Learning (OCL) uses a pattern separation paradigm to assess visual memory. The change from baseline of correct responses on the OCL task up to Week 8 is compared in participants receiving donepezil with participants receiving placebo. Change from baseline was the averaged correct response rate at Week 8 minus the correct response rate at baseline.

    Time frame: Baseline, Up to Week 8

Secondary outcomes

  1. Change From Baseline in Standard Deviation for Averaged Correct Response Rate on the OCL Task (Arcsine Square Root Transformed) to Week 8

    OCL uses a pattern separation paradigm to assess visual memory. Change in standard deviation from baseline for correct response rate on the OCL task up to Week 8 is compared in participants with mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD) receiving donepezil with participants receiving placebo. Change from baseline was the standard deviation for correct response rate at Week 8 minus the standard deviation for correct response rate at baseline. Standard deviations are reported in arcsine square root (sqrt) transformed correct response (CR) rate.

    Time frame: Baseline, Up to Week 8

  2. Change From Baseline in Averaged Correct Response Rate on the OCL Task to Week 8 in Participants Receiving Donepezil

    OCL uses a pattern separation paradigm to assess visual memory. The change from baseline of correct responses on the OCL task up to Week 8 in participants receiving donepezil is presented. Change from baseline was the averaged correct response rate at Week 8 minus the correct response rate at baseline. Per protocol, the placebo group was not included in this analysis.

    Time frame: Baseline, Up to Week 8

07

Results

Posted Oct 28, 2024

Participant flow

Treatment-naïve male and female participants with mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD) between the ages of 55 and 85 years (inclusive) will be enrolled in this trial.

Participant flow — Overall Study
MilestoneDonepezilPlacebo
Started2915
Completed2814
Not completed11
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange From Baseline in Averaged Correct Response Rate on the One Card Learning Task to Week 8

One Card Learning (OCL) uses a pattern separation paradigm to assess visual memory. The change from baseline of correct responses on the OCL task up to Week 8 is compared in participants receiving donepezil with participants receiving placebo. Change from baseline was the averaged correct response rate at Week 8 minus the correct response rate at baseline.

Time frame:
Baseline, Up to Week 8
Reported as:
Mean · Proportion of correct response
Change From Baseline in Averaged Correct Response Rate on the One Card Learning Task to Week 8
Proportion of correct responseDonepezilPlacebo
Change From Baseline in Averaged Correct Response Rate on the One Card Learning Task to Week 80.055 ± 0.0780.034 ± 0.091
Statistical analysis
  • Donepezil vs Placebo · Posterior probability: 46.30
SecondaryChange From Baseline in Standard Deviation for Averaged Correct Response Rate on the OCL Task (Arcsine Square Root Transformed) to Week 8

OCL uses a pattern separation paradigm to assess visual memory. Change in standard deviation from baseline for correct response rate on the OCL task up to Week 8 is compared in participants with mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD) receiving donepezil with participants receiving placebo. Change from baseline was the standard deviation for correct response rate at Week 8 minus the standard deviation for correct response rate at baseline. Standard deviations are reported in arcsine square root (sqrt) transformed correct response (CR) rate.

Time frame:
Baseline, Up to Week 8
Reported as:
Number · Arcsine sqrt transformed proportion CR
Change From Baseline in Standard Deviation for Averaged Correct Response Rate on the OCL Task (Arcsine Square Root Transformed) to Week 8
Arcsine sqrt transformed proportion CRDonepezilPlacebo
MCI0.0780.074
Mild AD0.0800.097
Statistical analysis
  • Donepezil · Posterior probability: 80.67
SecondaryChange From Baseline in Averaged Correct Response Rate on the OCL Task to Week 8 in Participants Receiving Donepezil

OCL uses a pattern separation paradigm to assess visual memory. The change from baseline of correct responses on the OCL task up to Week 8 in participants receiving donepezil is presented. Change from baseline was the averaged correct response rate at Week 8 minus the correct response rate at baseline. Per protocol, the placebo group was not included in this analysis.

Time frame:
Baseline, Up to Week 8
Reported as:
Mean · Proportion of correct response
Change From Baseline in Averaged Correct Response Rate on the OCL Task to Week 8 in Participants Receiving Donepezil
Proportion of correct responseDonepezilPlacebo
Change From Baseline in Averaged Correct Response Rate on the OCL Task to Week 8 in Participants Receiving Donepezil0.055 ± 0.078—
Statistical analysis
  • Donepezil · Posterior probability: 98.8

Adverse events

Collected over Up to Week 10 (up to 70 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil0/29 (0%)1/29 (3.4%)16/29 (55.2%)
Placebo0/15 (0%)0/15 (0%)4/15 (26.7%)
Most frequent serious events
Most frequent serious events
EventDonepezilPlacebo
PresyncopeNervous system disorders1/290/15
Most frequent other events
Showing 10 of 28
Most frequent other events
EventDonepezilPlacebo
DyspepsiaGastrointestinal disorders0/292/15
Upper respiratory tract infectionInfections and infestations3/290/15
Muscle spasmsMusculoskeletal and connective tissue disorders3/290/15
Abnormal dreamsPsychiatric disorders3/290/15
FatigueGeneral disorders2/291/15
Urinary tract infectionInfections and infestations2/290/15
HeadacheNervous system disorders2/291/15
Otitis mediaInfections and infestations0/291/15
DizzinessNervous system disorders0/291/15
PruritusSkin and subcutaneous tissue disorders0/291/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DonepezilPlaceboTotal
Mean68.3 ± 7.668.4 ± 7.768.4 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)DonepezilPlaceboTotal
Female171229
Male12315
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DonepezilPlaceboTotal
Hispanic or Latino12719
Not Hispanic or Latino17825
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DonepezilPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American9615
White19928
More than one race000
Unknown or Not Reported000
08

Study locations

10 sites
  • Collaborative Neuroscience Network ( Site 0010)
    Long Beach, California 90806, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0013)
    Hallandale Beach, Florida 33009, United States
  • Charter Research - Lady Lake ( Site 0025)
    Lady Lake, Florida 32159, United States
  • iResearch Atlanta ( Site 0005)
    Decatur, Georgia 30030, United States
  • iResearch Savannah ( Site 0023)
    Savannah, Georgia 31405, United States
  • Pennington Biomedical Research Center ( Site 0006)
    Baton Rouge, Louisiana 70808, United States
  • Insight Clinical Trials ( Site 0020)
    Beachwood, Ohio 44122, United States
  • North Texas Clinical Trials - Fort Worth - West Rosedale ( Site 0022)
    Fort Worth, Texas 76104, United States
  • Royal Adelaide Hospital-CALHN Memory Trials ( Site 0031)
    Adelaide, South Australia 5000, Australia
  • Austin Health ( Site 0030)
    Heidelberg, Victoria 3084, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2023, 21 months.

Results were first posted in Oct 2024, 1 year 9 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 21 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2021
First posted
Jan 29, 2021
StartActual
Mar 23, 2021
Primary completionActual
Jan 20, 2023
CompletionActual
Feb 6, 2023
Results first posted
Oct 28, 2024
Last update
Oct 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04730635
Responsible party
Sponsor
First posted
Jan 29, 2021
Start date
Mar 23, 2021
Primary completion
Jan 20, 2023
Completion
Feb 6, 2023
Results posted
Oct 28, 2024
Last update
Oct 28, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion